Illumina Microarray — Total Revenue increased by 3.2% to $96.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.1%, from $94.00M to $96.00M. Over 4 years (FY 2021 to FY 2025), Microarray — Total Revenue shows a downward trend with a -3.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market adoption or successful product penetration of microarray technologies, while a decrease suggests market saturation or a shift in customer preference toward alternative sequencing platforms.
This metric represents the total gross revenue generated from the sale of microarray-based products and associated servi...
Comparable to revenue figures for specialized diagnostic or genomic hardware segments at life science tool companies.
ilmn_segment_microarray_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $105.00M | $93.00M | $105.00M | $114.00M | $97.00M | $100.00M | $102.00M | $111.00M | $93.00M | $90.00M | $98.00M | $97.00M | $96.00M | $85.00M | $100.00M | $94.00M | $87.00M | $83.00M | $93.00M | $96.00M |
| QoQ Change | — | -11.4% | +12.9% | +8.6% | -14.9% | +3.1% | +2.0% | +8.8% | -16.2% | -3.2% | +8.9% | -1.0% | -1.0% | -11.5% | +17.6% | -6.0% | -7.4% | -4.6% | +12.0% | +3.2% |
| YoY Change | — | — | — | — | -7.6% | +7.5% | -2.9% | -2.6% | -4.1% | -10.0% | -3.9% | -12.6% | +3.2% | -5.6% | +2.0% | -3.1% | -9.4% | -2.4% | -7.0% | +2.1% |